To report a case of autoimmune thrombocytopenia due to chronic lymphocytic leukemia (CLL) treated with fludarabine.
CASE SUMMARY:
A 68-year-old white woman with CLL was treated with oral chlorambucil. She subsequently presented with severe autoimmune thrombocytopenia purpura (ITP). Intravenous gammaglobulin was administered without response, and a therapeutic splenectomy produced only a temporary response, with platelets reaching 65 times 103/mm3. Four weeks later, the platelet level was below 10 times 103/mm3. At that time, the woman was treated with fludarabine. The platelet count 4 weeks later was normal (270 times 103/mm3) and has been sustained for over 22 months.
DISCUSSION:
Fludarabine has been reported to be causative in the onset of autoimmune cytopenias with CLL. Our case cautiously suggests fludarabine as a potential treatment for cases of CLL-associated ITP refractory to standard therapy.
CONCLUSIONS:
Fludarabine could be considered as treatment of ITP in CLL refractory to standard treatment.
PlunkettW, GandhiV, HuangP, RobertsonLE, YangLY, GregoireV, et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol1993; 20 (5 suppl 7): 2–12.
2.
JohnsonS, SmithAG, LofflerH, OsbyE, GunnarJ, EmmerichB, et al. The French Cooperative Group on CLL: multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CDP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet1996; 347: 1432–8.
3.
RaiKR, BercedisL, PetersonB, AppelbaumFR, KolitzJ, EliasL, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med2000; 343: 1750–7.
4.
DighieroG, BinetJL. When and how to treat chronic lymphocytic leukemia. N Engl J Med2000; 343: 1799–801.
5.
PlunkettW, HuangP, GandhiV.Metabolism and action of fludarabine phosphate. Semin Oncol1990; 17 (suppl 8): 3–17.
6.
BoldtDH, Von HoffDD, KuhnJG, HershM.Effects on human peripheral lymphocytes of in vivo administration of 9-β-d-arabinofuranosyl-2-fluoroadenine-5′ monophosphate (NSC 312887), a new purine metabolite. Cancer Res1984; 44: 4661–6.
7.
KeatingMJ, KantarijanH, TalpazM, RedmanJ, KollerC, BarlogieB, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood1998; 74: 19–25.
8.
Di RaimondoF, GiustolisiR, CacciolaE, O'BrienS, KantarjianH, RobertsonLB, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma1993; 11: 63–8.
9.
LeachM, ParsonsRM, ReillyJT, WinfieldDA. Autoimmune thrombocytopenia: a complication of fludarabine therapy in lymphoproliferative disorders. Clin Lab Haematol2000; 22: 175–8.
10.
BayJO, FouassierM, BealD, AlcarazL, CureH, CholletP, et al. Autoimmune thrombocytopenia after six cycles of fludarabine in a patient with chronic lymphocytic leukemia. Hematol Cell Ther1997; 39: 209–12.
11.
MyintH, CopplestoneJA, OrchardJ, CraigV, CurtisD, PrenticeAG, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukemia. Br J Haematol1995; 91: 341–4.
12.
WeissRB, FreimanJ, KwederSL, DiehlLF, ByrdJC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol1998; 16: 1885–9.
McMillanR.Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med1997; 126: 307–14.
18.
GeorgeJN, KojouriK, PerdueJJ, VesleySK. Management of patients with chronic, refractory idiopathic thrombocytopenia purpura. Semin Hematol2000; 37: 290–8.
19.
BorcheL, LimA, BinetJL, DighieroG.Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood1990; 76: 562–9.
20.
Caligaris-CappioF.B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood1996; 87: 2615–20.
21.
PritschO, MaloumK, DigherioG.Basic biology of autoimmune phenomena in chronic lymphocytic leukemia. Semin Oncol1998; 25: 34–41.
22.
KippsTJ, CarsonDA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood1993; 81: 2475–87.
23.
Caligaris-CappioF.Cellular interactions, immunodeficiency and autoimmunity in CLL. Hematol Cell Ther2000; 42: 21–5.
24.
MontilloM, TedeschiA, LeoniP.Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia. Leuk Lymphoma1994; 15: 187–8.
25.
TostiS, CarusoR, D'AdamoF, PicardiA, Ali EgeM, GirelliG, et al. Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Ann Hematol1992; 65: 238–9.
26.
RibeiroI, TsatalasC, CatovskyD.Treatment of red cell aplasia in CLL with fludarabine (letter). Leukemia1999; 13: 1897.
27.
SerraS, RealE, PastorE, GrauE.Refractory pure red-cell aplasia associated with B chronic lymphocytic leukemia treated by fludarabine. Haematologica1999; 84: 1154–5.
28.
JaccardA, OksenhendlerE, ClauvelJP. Cytopenia and fludarabine. Lancet1993; 342: 1049–50.
29.
BulvikS, PolliackA.Severe resistant immune thrombocytopenic purpura (ITP) complicating chronic lymphocytic leukemia (CLL) responding to a combination of fludarabine and danazol (abstract 3076). Blood1997; 90 (suppl 1): 82b–3b.
